91392-33-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Nitrophenyl)cyclopentanecarbonitrile is used as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its unique structure allows for the development of new drugs with improved efficacy and selectivity, contributing to the advancement of medicine and healthcare.
Used in Chemical Synthesis:
1-(4-Nitrophenyl)cyclopentanecarbonitrile is used as a building block in the synthesis of complex organic molecules, including natural products, agrochemicals, and other specialty chemicals. Its versatile structure enables the creation of a wide range of compounds with diverse properties and applications, making it an essential component in the field of organic chemistry.
Used in Research and Development:
1-(4-Nitrophenyl)cyclopentanecarbonitrile is utilized as a research tool in the development of new synthetic methods and strategies. Its unique structure provides opportunities for chemists to explore novel reactions and mechanisms, leading to the discovery of more efficient and sustainable synthetic routes for the production of valuable compounds.

InChI:InChI=1/C12H12N2O2/c13-9-12(7-1-2-8-12)10-3-5-11(6-4-10)14(15)16/h3-6H,1-2,7-8H2

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 555-21-5 4-Nitrophenylacetonitrile 
• 77-57-6 1-phenyl-1-cyclopentanecarbonitrile 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 115279-73-7 1-(4-aminophenyl)cyclopentane-1-carbonitrile 
• 1030574-53-8 1-(4-nitro-phenyl)-cyclopentanecarboxylic acid amide 
• 1158560-99-6 N-[4-(1-cyanocyclopentyl)phenyl][2-chloro(3-pyridyl)]carboxamide 
• 1275609-09-0 N-[4-(1-cyanocyclopentyl)phenyl][2-[(4-pyridylmethyl)amino](3-pyridyl)]carboxamide 
• 1067192-39-5 [1-(4-nitro-phenyl)-cyclopentyl]-carbamic acid methyl ester 
• 52648-77-8 1-(4-nitro-phenyl)-cyclopentanecarboxylic acid 

Relevant academic research and scientific papers

CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES

A chemoselective and reactive Mn(CF3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

Preparation method of apatinib intermediate

A preparation method of an apatinib intermediate belongs to the technical field of chemical synthesis of medicines. The preparation method comprises the following steps: nitration reaction: dropwise adding 1-phenyl-1-cyclohexonitrile as a compound II into a mixed acid of phosphoric acid, nitric acid and sulfuric acid, and stirring for reaction to obtain an apatinib intermediate primary product asa compound I; and refining: refining the obtained apatinib intermediate primary product by using a refining solvent to obtain an apatinib intermediate finished product serving as a compound I. The usage amount of nitric acid and concentrated sulfuric acid is remarkably reduced, and the pressure on the environment influence is reduced; the purity is high; the preparation cost is reduced; the stepsare simple and reasonable, the operation is convenient, and tedious post-treatment is avoided; and the preparation method is beneficial for obtaining raw material medicines with higher quality.

SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Apatinib preparation method

The present invention relates to an apatinib preparation method, wherein specifically an organic solvent is selected to perform refining crystallization to obtain the apatinib. The method of the present invention has advantages of simple operation and low cost, and is suitable for large-scale production.

NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE

The present invention provides new compounds of formula I, wherein Q, R1, R2, R4, R5, R6, Xi, R7, R8, M and G1 nare defined as in formula I; invention compounds are modulators of follicle-stimulating hormone - ("FSH") which are useful for male and female contraception as well as other disorders modulated by FSH receptor.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, es

1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS

The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Inhibitors of Acyl-CoA: Cholesterol Acyltransferase (ACAT). 7. Development of a Series of Substituted N-Phenyl-N'-ureas with Enhanced Hypocholesterolemic Activity

We recently described our initial structure-activity relationship (SAR) studies on a series of N-phenyl-N'-aralkyl- and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT).From this series of analogs, compou

Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds

Certain substituted urea, thiourea, carbamate, and thiocarbamate compounds are potent inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol, and for lowering blood